Clinical TrialJul 12, 2026, 09:31 AM
Evaxion Presents New Data Supporting EVX-V1 CMV Vaccine Program
AI Summary
Evaxion A/S presented new data supporting its multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, at the International Herpesvirus Workshop 2026. The data demonstrated that AI-Immunology™ discovered novel T-cell epitopes have the potential to improve control of acute infection, latency, and reactivation in CMV-infected mice. This builds on previous findings showing the vaccine's ability to reduce viral infection and mediate superior viral neutralization, further strengthening the protective potential of EVX-V1.
Key Highlights
- New data for EVX-V1 CMV vaccine presented at International Herpesvirus Workshop 2026.
- EVX-V1 combines AI-discovered antigens with AI-optimized established CMV vaccine antigens.
- AI-discovered T-cell epitopes showed potential to improve control of acute infection, latency, and reactivation in mice.
- Previous data indicated novel B-cell antigens reduced viral infection and optimized gB antigens mediated superior viral neutralization.
- CMV treatment market was $474.6 million in 2023, with a projected 6.6% CAGR (2024-2032).
Price Impact
More from EVAX